Heartflow and Cleerly Fight Over the Future of Cardiac AI Competition
Heartflow’s lawsuit against AI rival Cleerly highlights how competitive pressure in cardiovascular imaging is shifting from clinical validation to intellectual property. The dispute suggests the market is maturing enough that legal strategy now matters alongside algorithm performance.
The Heartflow-Cleerly dispute is significant because it shows cardiovascular AI has moved beyond proof-of-concept competition. Once a category reaches meaningful commercial traction, the strategic battlefield expands: patents, platform differentiation, and market positioning become as important as the science behind the algorithm.
That evolution is not surprising. Cardiac imaging is one of the most attractive clinical AI markets because it combines high-value diagnostics, measurable outcomes, and clear pathways for reimbursement discussions. But those same features also make the space fiercely contested, especially as companies seek to define what counts as proprietary analysis versus standard computational workflow.
For hospitals and clinicians, the legal fight may feel remote, yet it can have real downstream effects. IP disputes can slow partnerships, complicate procurement, and create uncertainty around which tools will remain supported or affordable. In a field that depends on trust and longitudinal validation, that kind of instability matters.
The broader takeaway is that AI in cardiology is entering a more mature phase. Innovation is no longer just about demonstrating an FDA-cleared model; it is about building defensible products, durable commercial relationships, and evidence that can survive both clinical scrutiny and competitive attack.